Novel Tinnitus Implant System for the Treatment of Chronic Severe Tinnitus

Matthew L. Carlson, M.D.9 enrolled

Overview

Researchers are gathering information on the safety and effectiveness of a novel device called the Tinnitus Implant System for the treatment of tinnitus.

This study requires one year of participation with at least 21 visits to Mayo Clinic in Rochester MN for device programming and audiometric testing. The device is implanted during an outpatient surgery. Participants may keep the study device after participation is complete.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Tinnitus

Interventions

Tinnitus Implant SystemDEVICE

Device will deliver stimulation below hearing thresholds continuously or intermittently.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria * Age: ≥18 years of age * Normal to moderate SNHL (≤70 dB HL; based on PTA of 0.5, 1 and 2 kHz) and WRS ≥ 75%. * Unilateral or asymmetrical subjective tonal tinnitus * Tinnitus present for at least 6 months, but not longer than 3 years * Tinnitus that is disruptive * THI score in the severe range (≥56/100) * TFI score in the severe range (≥52/100) * Tinnitus VAS ≥50/100 * Tinnitus that is intractable, and has not been ameliorated by conventional measures such as a hearing aid or masking Exclusion Criteria * Age: \<18 years of age * Tinnitus present less than 6 months or longer than 3 years * Current pregnancy * History of brain or major ear surgery * Prior major head trauma * Presence of clinically significant depressive or anxiety symptoms determined by screening using the GAD-7, PHQ-8, and SHAI * GAD-7 \>9 (indicates clinically significant anxiety) * PHQ-8 \>9 (indicates clinically significant depression) * SHAI \>25 (hypochondriacal level illness anxiety) * Inability to assess, continue or complete trial * Currently on antidepressants, anxiolytics or antipsychotics * Active use of other tinnitus treatments (not including non-masking hearing aid use) * Normal contrast-enhanced MRI of the head * Normal temporal bone CT

Locations (1)

Mayo Clinic in Rochester

Rochester, Minnesota, United States

Outcomes

Primary Outcomes

Number of subjects with treatment-related adverse events

Measured by subjects meeting one or more of the following criteria: worsening bone conduction thresholds in any tested frequency (0.25, 0.5, 1, 1.5, 2, 3, or 4 kHz) from baseline by a clinically significant amount (\>10 dB) or worsening in WRS from baseline by a clinically significant amount (\>20%) or worsening in video head impulse test result from baseline or one or more serious AEs

Time frame: One year

Number of subjects to experience significant improvement from implantation of the device

Measured by subjects meeting at least two of three measurements of tinnitus severity: Tinnitus Handicap Inventory (THI) improvement by greater than 7 points using a 25-item self-assessment questionnaire with possible answers of Yes (4 points), Sometimes (2 points), and No (0 points) or Tinnitus Functional Index (TFI) improvement by greater than 13 points using a 25-item self-report questionnaire on a scale of 0 to 10 with a maximum possible score of 250 or Tinnitus visual analog scale improvement by greater than 15 points using a self-reported scale consisting of a 10 cm line with verbal descriptors (word anchors) at each end to express the extremes of the symptom; 0 mm designates no pain and 100 mm designates the greatest imaginable severity of pain.

Time frame: Baseline, 3 weeks, 5 weeks, 7 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 13 weeks, 14 weeks, 15 weeks, 52 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.